ストックスクリーナーアプリを入手
0.727
10.02%
-0.081
プレマーケット:
.71
-0.017
-2.34%
前日終値:
$0.808
開ける：
$0.808
24時間の取引高:
105.68K
Relative Volume:
0.34
時価総額：
$2.69M
収益：
-
当期純損益:
$-11.53M
株価収益率:
-0.1508
EPS:
-4.82
ネットキャッシュフロー:
$-11.12M
1週間 パフォーマンス:
-12.01%
1か月 パフォーマンス:
-14.47%
6か月 パフォーマンス:
-55.40%
1年 パフォーマンス:
-99.19%
1日の値動き範囲:
$0.711
$0.808
1週間の範囲:
$0.711
$0.912
52週間の値動き範囲:
$0.711
$5.9099
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
名前
Processa Pharmaceuticals Inc
セクター
電話
443-776-3133
住所
7380 COCA COLA DRIVE, HANOVER
PCSA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
0.727 | 2.69M | 0 | -11.53M | -11.12M | -4.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-25 | 開始されました | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc (PCSA) 最新ニュース
PROCESSA PHARMACEUTICALS, INC. : Regulation FD Disclosure (form 8-K) -June 09, 2021 at 01:17 pm EDT - Marketscreener.com
Processa Pharmaceuticals stock hits 52-week low at $0.8 - MSN
Processa Pharmaceuticals stock hits 52-week low at $0.8 By Investing.com - Investing.com South Africa
Processa Pharmaceuticals (NASDAQ:PCSA) Stock Price Down 0.6% – Here’s Why - Defense World
Processa Pharmaceuticals stock hits 52-week low at $0.81 By Investing.com - Investing.com South Africa
Processa Pharmaceuticals stock hits 52-week low at $0.81 - Investing.com
Gastroparesis Treatment Market Investment Opportunities: A Guide to 2031 | Evoke Pharma, Inc., Processa - EIN News
Processa Pharmaceuticals stock hits 52-week low at $0.85 By Investing.com - Investing.com Australia
Processa Pharmaceuticals stock hits 52-week low at $0.85 - Investing.com
Diabetic Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharma, Takeda - The Globe and Mail
Diabetic Gastroparesis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Theravance Biopharma, Eli Lilly and Company, Processa Pharmaceuticals, PTC Therapeutics - The Globe and Mail
Why C3.ai Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Benzinga
What is HC Wainwright’s Forecast for PCSA FY2024 Earnings? - Defense World
Gastroparesis Drugs Market to Grow by USD 1.42 Billion (2024-2028), Diabetes Burden Boosts Growth, AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Processa Pharmaceuticals stock hits 52-week low at $1.04 By Investing.com - Investing.com Australia
Processa Pharmaceuticals stock hits 52-week low at $1.04 - Investing.com India
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve
Processa Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks
Processa Pharmaceuticals stock hits 52-week low at $1.18 - Investing.com
Processa Pharmaceuticals stock hits 52-week low at $1.18 By Investing.com - Investing.com UK
Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results - The Manila Times
Processa Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Colorectal Cancer Pipeline Overview 2024: FDA Approvals and Key Companies involved by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa Pharma - The Globe and Mail
Gastroparesis Treatment Market Size, Demand, Trends, Analysis - openPR
processa pharmaceuticals inc. Earnings dates - RTTNews
Analytical Lens: Exploring Processa Pharmaceuticals Inc (PCSA)’s Financial Story Through Ratios - The Dwinnex
Processa stock rallies 35% post-market on Phase 2 study update - MSN
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer - ForexTV.com
Constellation Brands, Levi Strauss And 3 Stocks To Watch Heading Into Thursday - Benzinga
Pure Storage, Inc. (NYSE:PSTG) CRO Sells $450,709.65 in Stock - Defense World
Peraso Inc’s latest rating changes from various analysts - Knox Daily
Progress Software (PRGS) Q3 Earnings and Revenues Surpass Estimates - Yahoo Finance
Progress Software Stock Jumps On Q3 Earnings: Revenue Beat, EPS Beat, Raised Guidance And More - TradingView
Progress Software Corp (PRGS) Q3 2024 Earnings: EPS of $0.65 Bea - GuruFocus.com
Perrigo shares downgraded amid restructuring efforts - Investing.com India
Jefferies Financial Group Boosts Pacira BioSciences (NASDAQ:PCRX) Price Target to $18.00 - Defense World
A Look at Pacira BioSciences Inc (PCRX) Shares in the Recent Past Indicates Growth - SETE News
Check out these key findings about Privia Health Group Inc (PRVA) - SETE News
Sagefield Capital LP Acquires 1,023,527 Shares of Permian Resources Co. (NASDAQ:PR) - Defense World
Precigen Inc (PGEN)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Monitoring Perrigo Company plc (PRGO) after recent insider movements - Knox Daily
Pacira price target raised to $18 from $15 at Jefferies - TipRanks
Get in on PureCycle Technologies Inc’s (PCT) buy-in window today! - SETE News
72,064 Shares in Primoris Services Co. (NASDAQ:PRIM) Acquired by Appian Way Asset Management LP - MarketBeat
Financial Snapshot: Analyzing PureCycle Technologies Inc (PCT)’s Key Ratio Metrics - The Dwinnex
Primoris Services Co. (NASDAQ:PRIM) Shares Sold by Paradigm Capital Management Inc. NY - Defense World
Dimensional Fund Advisors LP Has $108.58 Million Position in Perdoceo Education Co. (NASDAQ:PRDO) - Defense World
Rs 5,890 Crore Order Book: Construction Company Secures Orders Worth Rs 554.92 Crore, FY25 Order Inflows Reach Rs 1,444.91 Crore – FIIs and DIIs Significantly Increase Stake - Dalal Street Investment Journal
Should We Be Delighted With Poste Italiane S.p.A.'s (BIT:PST) ROE Of 18%? - Simply Wall St
ProSiebenSat.1 Media (OTCMKTS:PBSFY) Shares Up 8.7% - Defense World
Precigen Inc (PGEN) may enjoy gains as insiders got busy in the recent days - Knox Daily
Processa Pharmaceuticals Inc (PCSA) 財務データ
収益
当期純利益
現金流量
EPS
Processa Pharmaceuticals Inc (PCSA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Young David | Pres. Research & Development |
Feb 06 '24 |
Buy |
2.53 |
20,000 |
50,504 |
58,387 |
| Lin Patrick | Chief Business - Strategy Off |
Jan 31 '24 |
Buy |
2.37 |
2,500 |
5,925 |
25,978 |
| Lin Patrick | Chief Business - Strategy Off |
Feb 01 '24 |
Buy |
2.40 |
1,500 |
3,600 |
27,478 |
| Ng George K | Chief Executive Officer |
Jan 30 '24 |
Buy |
2.70 |
10,000 |
27,000 |
20,000 |
| Yorke Justin W | Director |
Jan 30 '24 |
Buy |
2.69 |
8,000 |
21,544 |
31,232 |
4.81%
大文字化:
|
ボリューム (24 時間):